Increlex

Drug Overview

In the clinical specialty of Endocrinology, particularly within the study of the somatotropic axis, the management of growth failure requires a precise understanding of the signaling pathway between the pituitary gland and peripheral tissues. Increlex is a high-potency pharmaceutical intervention belonging to the IGF-1 Analog drug class. It contains Mecasermin, which is a recombinant human insulin-like growth factor-1 (rhIGF-1) produced by DNA technology. It is identical to the endogenous 70-amino acid protein naturally produced by the human body.

Increlex serves as a vital Hormone Replacement Therapy for children with severe Primary IGF-1 Deficiency. As a Targeted Therapy, it is specifically engineered for patients who have “Growth Hormone Resistance,” meaning their bodies produce Growth Hormone (GH), but their liver and bones are unable to respond to it to produce the IGF-1 necessary for linear growth.

• Generic Name: Mecasermin [rhIGF-1]
• US Brand Names: Increlex
• Drug Class: IGF-1 Analog / Growth Factor
• Drug Category: Endocrinology / Pediatric Growth Disorders
• Route of Administration: Subcutaneous injection
• FDA Approval Status: FDA-approved (2005) for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency.
  
  Increlex (mecasermin) is an IGF-1 analog for treating severe primary IGF-1 deficiency. Get specialized pediatric endocrine care with our experts.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Increlex functions, one must examine the Hypothalamic-Pituitary-Somatotropic Axis. In a healthy physiological state, the pituitary gland secretes Growth Hormone (GH), which travels to the liver to stimulate the production of IGF-1. IGF-1 is the actual effector molecule that tells the bones to grow.

The “Broken Bridge” (GH Resistance)

In patients with severe Primary IGF-1 Deficiency (including Laron syndrome), the bridge between GH and IGF-1 is broken.

1. GH Insensitivity: The GH receptors are either missing or dysfunctional.
2. Downstream Failure: Even if the body has high levels of GH, the liver cannot produce IGF-1.
3. Growth Failure: Without IGF-1, the chondrocytes (cartilage cells) in the growth plates do not proliferate, resulting in extreme short stature.

Molecular Signaling

Increlex acts as a “molecular bypass.” At the cellular level:

• Direct Activation: By injecting rhIGF-1 directly, the medication bypasses the non-functional GH receptors.
• Skeletal Stimulation: It binds to the Type 1 IGF-1 receptor, triggering the MAPK and PI3K signaling pathways.
• Anabolic Growth: This stimulates the uptake of amino acids and glucose into muscle and bone, promoting osteoblast/osteoclast activity and longitudinal bone growth.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Increlex is Mecasermin for severe Primary IGF-1 Deficiency (SPIGFD). This is defined by:

• Height standard deviation score ≤−3.0.
• Basal IGF-1 standard deviation score ≤−3.0.
• Normal or elevated GH levels (ruling out GH deficiency).

Other Approved & Off-Label Uses

Within the broader landscape of Endocrinology:

• GH Gene Deletion: For patients who have developed neutralizing antibodies to Growth Hormone.
• Laron Syndrome: The classic genetic form of GH insensitivity.
• Primary Endocrinology Indications:
  • Promotion of linear growth in children who have failed GH therapy due to resistance.
  • Normalization of metabolic parameters associated with low IGF-1, such as lipid profiles and bone mineral density.
  • Stabilization of the Hypothalamic-Pituitary-Adrenal (HPA) Axis by improving overall body composition and reducing metabolic stress.

Dosage and Administration Protocols

Dosing for Increlex is highly sensitive and must be adjusted carefully to balance growth with the risk of metabolic side effects.

Parameter	Clinical Specification
Starting Dose	0.04 to 0.08 mg/kg
Maintenance Target	Up to 0.12 mg/kg
Frequency	Twice daily (BID)
Timing	Immediately before or after a meal/snack

Export to Sheets

Specialized Administration Protocols

• The “Sugar Rule”: Because IGF-1 is structurally similar to insulin, it can lower blood sugar. Increlex must never be administered if the child cannot eat or misses a meal.
• Injection Technique: Administered subcutaneously in the thigh, abdomen, or upper arm.
• Titration: If the starting dose is tolerated for one week without hypoglycemia, the dose is increased in increments of 0.04 mg/kg.
• Site Rotation: Essential to prevent localized fat pad changes (lipohypertrophy).

Clinical Efficacy and Research Results

Clinical data through 2026 confirms that Increlex is the only effective non-surgical intervention for children with GH resistance.

Numerical Data and Results

• Height Velocity: In pivotal trials, children treated with Increlex showed a mean increase in growth velocity from ~2.8 cm/year to 8.0–8.5 cm/year in the first year of therapy.
• Cumulative Growth: Research results highlight a mean total height gain of approximately 13 to 15 cm over the first three years of treatment.
• Metabolic Impact: Numerical data indicates a significant improvement in lean body mass and a reduction in visceral fat, which is often elevated in children with IGF-1 deficiency.
• Bone Maturity: Research (2025) confirms that while linear growth is rapid, bone age typically advances in proportion to height age, preventing premature growth plate closure.

Safety Profile and Side Effects

The primary safety concern with Increlex is its “insulin-like” effect on glucose metabolism.

Common Side Effects (>10%)

• Hypoglycemia: The most significant risk; occurs in approximately 30% of patients. Symptoms include dizziness, sweating, and confusion.
• Tonsillar/Adenoidal Hypertrophy: IGF-1 can cause growth of lymphatic tissue, leading to snoring or sleep apnea.
• Lipohypertrophy: Thickening of the fat at the injection site.
• Arthralgia: Joint pain related to rapid growth.

Serious Adverse Events

• Intracranial Hypertension: Characterized by severe headaches, papilledema, and visual changes (similar to GH therapy).
• Slipped Capital Femoral Epiphysis (SCFE): A hip condition that can occur during periods of rapid linear growth.
• Scoliosis Progression: Rapid growth can exacerbate existing spinal curvature.
• Allergic Reactions: Rare systemic hypersensitivity to the rhIGF-1 protein.

Research Areas (2024–2026)

Direct Clinical Connections

Active research in 2026 is investigating the drug’s impact on Pancreatic Beta-cell Preservation. While high doses of IGF-1 can cause hypoglycemia, physiological replacement may actually improve overall Insulin Sensitivity in the long term by reducing the liver’s production of glucose and lowering the “metabolic burden” on the pancreas.

Generalization and Advancements

The field is moving toward advancements in Novel Delivery Systems, specifically “IGF-1 Binding Protein (IGFBP-3) Complexes.” By binding rhIGF-1 to its natural carrier protein, researchers hope to create a longer-acting version that reduces the risk of acute hypoglycemia. Furthermore, research into the HPA Axis is evaluating how IGF-1 replacement therapy affects the body’s cortisol rhythm and overall stress resilience.

Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is not yet applicable to all clinical scenarios or standard of care protocols. 

Patient Management and Clinical Protocols

Monitoring and Precautions

• Vigilance: Blood glucose should be monitored closely during the first month of therapy and after any dose increase.
• Physical Exams: Regular screening for tonsillar enlargement and scoliosis is required every 6 months.
• Imaging: Fundoscopic exams (eye checks) are recommended if the child develops persistent headaches.
• Lifestyle: Medical Nutrition Therapy (MNT) must prioritize consistent carbohydrate intake to provide a “glucose buffer” for the medication’s effects.

“Do’s and Don’ts”

• DO keep a source of fast-acting sugar (like juice or glucose tabs) nearby at all times.
• DO store the vial in the refrigerator and discard it 30 days after the first puncture.
• DON’T give the injection if the child is sick and refusing to eat.
• DON’T increase the dose to “make up” for missed doses.

Legal Disclaimer

This document is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. Increlex must be used under the strict supervision of a pediatric endocrinologist. Incorrect administration can lead to severe, life-threatening hypoglycemia.